The emerging class of GLP-1 receptor and GIP dual medications, including tirzepatide, semaglutide, and the relatively introduced retatrutide, provide promising advances in the treatment . Despite all three https://semaglutide552690.getblogs.net/76458171/semaglutide-a-detailed-look